COMPASS THERAPEUTICS (CMPX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CMPX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CMPX | Director | 67 | [] | [] | 2026 |
Biography sourced from the proxy statement filing.
Ellen V. Chiniara, J.D., joined the Compass Board of Directors in April of 2022. In September of 2025, Ms. Chiniara retired from her role as chief legal officer and corporate secretary of biopharmaceutical company Kymera Therapeutics, Inc. (Nasdaq: KYMR), a position she had held since January of 2023. Ms. Chiniara previously served as executive vice president, chief legal officer and corporate secretary of Alexion Pharmaceuticals, Inc., a pharmaceutical company from January of 2018 until its acquisition by AstraZeneca PLC (LSE/Nasdaq: AZN) in July 2021. In this role, she was responsible for all global legal and intellectual property matters. Prior to joining Alexion, Ms. Chiniara was senior vice president, general counsel and corporate secretary of Alere Inc., a point-of-care diagnostics company, from October 2006 to its acquisition by Abbott Laboratories (NYSE: ABT) in October 2017. She was responsible for all legal matters and government affairs and, in June 2014 she assumed oversight of compliance matters. Earlier in her career, Ms. Chiniara was a partner at the law firm Hale and Dorr LLP (now Wilmer Cutler Pickering Hale and Dorr LLP). Ms. Chiniara received her J.D. from Stanford University s School of Law and her B.A. from Bryn Mawr College. We believe that Ms. Chiniara is qualified to serve on our Board of Directors based on her extensive industry experience and expertise in legal, compliance, and governance matters.